Skip to main content
Equibles

Stephen Mahoney

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Stephen Mahoney

Stephen Mahoney was last confirmed as Board Member at Dianthus Therapeutics, Inc. /DE/ (DNTH) in a filing dated May 2, 2022. Dianthus Therapeutics, Inc. /DE/ reported in an 8-K filed September 12, 2023 that Stephen Mahoney was terminated as President, Chief Financial and Operating Officer, effective September 11, 2023. The proxy statement of Dianthus Therapeutics, Inc. /DE/ reports total compensation of $1,656,676 for Stephen Mahoney in fiscal 2023, including a base salary of $309,257. Disclosed compensation is on record for 3 fiscal years.

“Immediately after closing of the Merger, Stephen Mahoney, President, Chief Financial and Operating Officer, was terminated without cause as part of the transaction and is pursuing other opportunities.”
Dianthus Therapeutics, Inc. /DE/ Form 8-K, filed September 12, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Dianthus Therapeutics, Inc. /DE/ (DNTH) $309,257 $1,656,676
2022 Dianthus Therapeutics, Inc. /DE/ (DNTH) $448,000 $1,120,887
2020 Dianthus Therapeutics, Inc. /DE/ (DNTH) $70,000 $1,959,130

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.